- Market Capitalization, $K 353,353
- Shares Outstanding, K 197,404
- Annual Sales, $ 5,630 K
- Annual Income, $ -44,580 K
- 60-Month Beta -1.73
- Price/Sales 57.12
- Price/Cash Flow N/A
- Price/Book 4.99
|Period||Period Low||Period High||Performance|
| || |
-0.2350 (-12.05%)since 09/30/20
| || |
-0.8750 (-33.78%)since 07/30/20
| || |
+0.4150 (+31.92%)since 10/30/19
Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2020 financial results at approximately 4:00 PM Eastern Time on Monday, November 9, 2020, and will host a conference call shortly thereafter...
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
The FDA bestows a Regenerative Medicine Advanced Therapy status on Athersys' (ATHX) MultiStem cell therapy candidate for treating acute respiratory distress syndrome.
Advancements in stem cell research is a major driving factor for the global acute respiratory distress syndrome treatment market growth. According to the National Centre for Biotechnology Information (NCBI),...
Athersys, Inc., a leading regenerative medicine company in late-stage clinical development, announced today that MultiStem(R) cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation...
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2020.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SINT, CAAS, ATHX, THTX, and BIOC.
Athersys, Inc. (NASDAQ: ATHX) announced today its participation in several sessions at this year's International Society for Cell and Gene Therapy (ISCT) virtual conference taking place May 28 - 29, 2020....
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2020.